Improve triage with FAM19A4/miR124-2 methylation analysis

The transition to high-risk human papillomavirus (hrHPV) testing as the primary screening method for cervical cancer is gaining traction worldwide due to its objectivity, high throughput, and superior sensitivity compared to cytology. However, distinguishing clinically relevant infections from transient ones remains a challenge, leading to higher rates of unnecessary colposcopy referrals. Triage methods for hrHPV-positive women must balance high sensitivity, specificity, and predictive values while minimizing additional sample requirements and patient burden. Various approaches, including DNA methylation analysis, are being explored to improve triage accuracy and efficiency. Fujirebio highlights FAM19A4/miR124-2 methylation analysis as a promising method with high sensitivity, specificity, and long-term safety, offering potential as an alternative to cytology for hrHPV-positive women.